The Drug Tariff Preface published monthly, lists additions, deletions and other changes to products listed in the Drug Tariff. Below is a summary of the changes coming into effect from 1 April 2025. From 1st April, the Single Activity Fee (SAF) will increase by 19p to £1.46 per item. For more information see CPCF arrangements for 2024/25 and [...]
The post Drug Tariff Watch – April 2025 appeared first on Community Pharmacy England.
Lagevrio has been deleted from Part VIIIC of the April 2025 Drug Tariff. This follows confirmation from the Department of Health and Social Care (DHSC) and Specialist Pharmacy Service that all remaining supplies of Government procured COVID-19 antiviral medicine Molnupiravir 200mg capsules (Lagevrio®) expired on 31 March 2025. Lagevrio® remains available for pharmacies to order [...]
The post Expiry of Government stockpile of Molnupiravir (Lagevrio®) 200mg capsules appeared first on Community Pharmacy England.
Following representations from Community Pharmacy England, the Department of Health and Social Care (DHSC) has re-determined that the following products will be granted special container status as complete pack sizes from April 2025: Cetraxal® 2mg/ml ear drops 0.25ml unit dose (Aspire Pharma Ltd) Cetraxal® Plus 3mg/ml + 0.25mg/ml ear drops 0.25ml unit dose (Aspire Pharma [...]
The post Cetraxal® preparations – change to special container status from sub-pack to complete pack appeared first on Community Pharmacy England.
From 1 April 2025, Progesterone micronised 200mg capsules (Gepretix®) has been added to the list of medicines covered by the HRT prepayment certificate (HRT PPC). This change has been reflected in Part XVI of the April 2025 Drug Tariff and on the NHSBSA’s website. Community Pharmacy England has also updated its HRT medicines list to [...]
The post Progesterone micronised 200mg capsules (Gepretix®) added to the HRT PPC medicines list from April 2025 appeared first on Community Pharmacy England.
MHRA Class 4 Medicines Notification: Sirdupla 25 microgram/250 microgram per metered dose pressurised inhalation, suspension (Cross Healthcare Limited) Drug alert number: EL(25)A/12 Date issued: 31 March 2025 Cross Healthcare Limited has informed the MHRA that there is a printing defect on the outer labels for the Sirdupla 25 microgram/250 microgram per metered dose pressurised inhalation, [...]
The post MHRA Class 4 Medicines Notification: Sirdupla 25 microgram/250 microgram per metered dose pressurised inhalation, suspension (Cross Healthcare Limited) appeared first on Community Pharmacy England.
Recent Comments